and Cann Group Medicinal Cannabis Partnership
Filed with ASX · · 1 page · English
Earlier from IDT Australia
- Appointment of Chief Executive Officer
- Update - Response to FDA Warning Letter
- IDT receives FDA Warning Letter
- Divestment of Selected Generic Product Portfolio
- Replacement Appendix 4D
Later from IDT Australia
- Preliminary Final Report
- On-Market Share Buy-back and Small Parcel Buy-back
- Investor Presentation to AGM
- Appendix 4D - Half Year Report
- IDT secures Medicinal Cannabis manufacturing license
Follow IDT Australia into a list and get an email when it puts out news.
Follow IDT Australia